Nancy Hutson joins BioCryst board
This article was originally published in Scrip
BioCryst Pharmaceuticals, a developer of small molecule drugs that block enzymes involved in infectious and inflammatory diseases and cancer, has appointed Dr Nancy Hutson to its board of directors. Dr Hutson retired from Pfizer in 2006 after spending 25 years in research and leadership positions, most recently serving as senior vice-president of global R&D and director of Pfizer's pharmaceutical R&D site. She currently serves on the boards of Cubist Pharmaceuticals and Endo Pharmaceutical Holdings.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.